In addition, phase I studies have shown that ATR inhibitors exhibit durable antitumor activity in patients with advanced cancers harboring ATM aberrations (ATM protein expression loss and/or ATM deleterious mutations)25,26. The gene discussed is ATR; the disease is cancer.